Overview

• Eli Lilly reported second-quarter revenue of $15.56 billion and adjusted earnings of $6.31 per share, topping Wall Street estimates.
• The company raised its full-year 2025 sales outlook to $60 billion–$62 billion and its adjusted EPS target to $21.75–$23, excluding planned U.S. import levies.
• Late-stage orforglipron data showed just over 12% body-weight loss at the highest dose, missing forecasts and triggering a more-than-12% premarket share decline.
• U.S. sales climbed 38% to $10.81 billion, driven by a 46% volume gain for Mounjaro and Zepbound and lifting Lilly’s incretin market share to 57%.
• President Trump’s letters demanding drug price cuts by Sept. 29 alongside proposed pharmaceutical tariffs pose potential margin pressures.